BioAffinity Technologies Reports Growth Of 375% In CyPath Lung Tests Ordered And Processed Over The Past Three Months As Compared To The Previous Three Months
BioAffinity Technologies Reports Growth Of 375% In CyPath Lung Tests Ordered And Processed Over The Past Three Months As Compared To The Previous Three Months
Increasing physician interest, newly approved reimbursement code driving growth
醫生興趣增加，新批准的報銷法推動增長
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported accelerating growth of 375% in CyPath Lung tests ordered and processed over the past three months as compared to the previous three months. CyPath Lung is a noninvasive test to detect early-stage lung cancer.
生物技術公司BioAffinity Technologies, Inc.（納斯達克股票代碼：BIAF，BIAFW））是一家專注於早期癌症和肺部疾病檢測需求的生物技術公司，今天報告稱，與前三個月相比，過去三個月訂購和處理的CyPath肺部測試加速增長了375％。CyPath 肺是一種無創性測試，用於檢測早期肺癌。
bioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath Lung in preparation for expanding to the national market.
BioAffinity Technologies的目標是實現其先前宣佈的在德克薩斯州推出的限量測試市場的銷售預測，該計劃旨在完善Cypath Lung的未來定位和戰略洞察力，爲向全國市場擴張做準備。
"The introduction of our reimbursement code, completion of our branding, and expansion of our sales force have markedly contributed to the growing physician interest and adoption of our innovative, noninvasive CyPath Lung test. Increasing physician satisfaction and adoption have also been driven by the successful integration and efficient operation of our commercial laboratory, Precision Pathology Laboratory," bioAffinity Technologies' President and CEO Maria Zannes said. "Importantly, our sales growth has been in line with our expectations and bolsters our confidence in our ability to capitalize on the lung cancer diagnostics market projected to reach $4.7 billion by 2030."
“我們的報銷代碼的引入、品牌的完善以及銷售隊伍的擴大，顯著地促進了醫生對我們創新的無創CyPath肺部檢查的興趣和採用。我們的商業實驗室精密病理學實驗室的成功整合和高效運營也推動了醫生滿意度和採用率的提高。” BioAffinity Technologies總裁兼首席執行官瑪麗亞·贊內斯說。“重要的是，我們的銷售增長符合我們的預期，增強了我們對我們利用肺癌診斷市場的能力的信心，預計到2030年肺癌診斷市場將達到47億美元。”
Pulmonologists and other lung health specialists understand the critically important role of screening and early diagnosis in improving outcomes for those diagnosed with lung cancer and providing peace of mind for individuals at elevated risk of developing the disease. bioAffinity Technologies' commitment to noninvasive cancer detection is poised to reshape the landscape of lung health management by increasing early detection and treatment.
肺科醫生和其他肺部健康專家明白，篩查和早期診斷在改善肺癌確診者的預後以及讓患病風險較高的人高枕無憂方面起着至關重要的作用。BioAffinity Technologies對無創癌症檢測的承諾有望通過增加早期發現和治療來重塑肺部健康管理格局。
bioAffinity Technologies will release financial results for the fourth quarter and full year ended December 31, 2023, on April 1, 2024.
BioAffinity Technologies將於2024年4月1日發佈截至2023年12月31日的第四季度和全年財務業績。
About CyPath Lung
關於 CyPath Lung
CyPath Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage cancer can improve outcomes and increase patient survival.
CyPath Lung 使用先進的流式細胞儀和人工智能 (AI) 來識別患者痰液中表明惡性腫瘤的細胞群。自動數據分析有助於確定是否存在癌症或患者是否沒有癌症。Cypath Lung含有一種熒光卟啉TCPP，它優先被癌症和癌症相關細胞吸收。臨床研究結果表明，對於肺結節小於20毫米的高風險患者，Cypath Lung檢測肺癌的靈敏度爲92％，特異性爲87％，準確率爲88％。診斷和治療早期癌症可以改善預後並提高患者的存活率。
譯文內容由第三人軟體翻譯。